Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mafenide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
| ▸ | CA2 | P00918 | 17/20 | 0.71 |
| ▸ | CA1 | P00915 | 13/20 | 0.71 |
| ▸ | CA12 | O43570 | 8/20 | 0.71 |
| ▸ | CA9 | Q16790 | 8/20 | 0.71 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.71 |
| ▸ | CA7 | P43166 | 7/20 | 0.71 |
| ▸ | CA6 | P23280 | 6/20 | 0.71 |
| ▸ | CA5A | P35218 | 6/20 | 0.71 |
| ▸ | CA5B | Q9Y2D0 | 6/20 | 0.71 |
| ▸ | CA4 | P22748 | 5/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.56 |
| ▸ | CA3 | P07451 | 2/20 | 0.49 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mafenide SCHEMBL26127074 | 0.89 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| Mafenide SCHEMBL41627 | 0.89 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| Mafenide SCHEMBL27599824 | 0.87 | KDM4E (0.82) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| Mafenide SCHEMBL9295695 | 0.84 | CA2 (1.00) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| Mafenide SCHEMBL41628 | 0.84 | CA2 (1.00) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| Mafenide SCHEMBL6648930 | 0.83 | KDM4E (0.87) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| Mafenide SCHEMBL1072130 | 0.83 | CA2 (0.87) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| Mafenide SCHEMBL425524 | 0.82 | CA2 (1.00) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| Mafenide SCHEMBL1203324 | 0.82 | CA2 (1.00) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| Mafenide SCHEMBL686407 | 0.81 | CA2 (0.95) | SMN1; SMN2KDM4ECA2CA1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| US-20240059658-A1 | QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER | UNIV EMORY (US) | 2024-02-22 | — | — | US | disclosed |
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-4888327-A | EYE INFECTIONS | ALCON LABORATORIES, INC. (US) | 1989-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059658-A1 | QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER | MDM2, TP53, RECQL | SMN1; SMN2 3124/4885KDM4E 2602/4885CA2 2010/4885 |
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | CCR8, CCR1, CCR3 | SMN1; SMN2 4731/4885KDM4E 1941/4885CA2 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.